Sex Disparities in Chemo Use for Advanced Bladder Cancer

This article originally appeared here.
Share this content:
Sex Disparities in Chemo Use for Advanced Bladder Cancer
Sex Disparities in Chemo Use for Advanced Bladder Cancer

FRIDAY, June 10, 2016 (HealthDay News) -- Among patients with stage IV bladder cancer, women are less likely than men to receive systemic chemotherapy, and they have lower overall survival (OS), according to a study published online May 25 in Cancer.

Tracy L. Rose, M.D., M.P.H., from the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, and colleagues compared sex differences in demographics, systemic chemotherapy administration, and OS for all patients diagnosed with stage IV bladder cancer from 1998 through 2010, identified using the National Cancer Data Base.

The researchers identified 23,981 patients (35 percent female). There was no difference in the Charlson-Deyo comorbidity score for men and women. Compared with men, women were less likely to receive systemic chemotherapy (45 versus 52 percent; adjusted relative risk, 0.91). Compared with men, women had a lower median OS (8.0 versus 9.8 months; P < 0.001). On multivariate analysis, women had lower OS, even after adjustment for administration of systemic chemotherapy (hazard ratio for death, 1.11).

"Women are less likely than men to receive systemic chemotherapy for advanced bladder cancer and this difference may partially account for the poorer OS observed in women," the authors write. "However, OS remains lower in women independent of chemotherapy use, and may be related to unmeasured comorbidities, functional status, or tumor biology."

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »